NovaBone Products

What NovaBone Products does

NovaBone Products, LLC is a privately held U.S. biomaterials company founded in 2002 and headquartered in Alachua, Florida, operating as a wholly-owned subsidiary of Halma PLC (FTSE 100) since 2020. The company develops, manufactures, and distributes synthetic bone graft substitutes and regenerative devices for dental and orthopedic surgeons across more than 40 countries, with product registrations in 46 jurisdictions. Its portfolio serves two primary verticals — orthopedic surgery (spine, foot and ankle, trauma) and dental surgery (periodontal, implant, sinus lift, ridge augmentation) — through brands including NovaBone Putty, NovaBone IRM, NovaBone Dental Putty, Porous Granules, MIS Delivery System, and the newer NovaForm Wound Matrix for advanced wound care.

The company's core technology is the proprietary 45S5 Bioglass (Calcium Sodium Phosphosilicate) platform, originating from Dr. Larry Hench's research at the University of Florida. Unlike purely osteoconductive graft materials, NovaBone's formulations claim the first FDA-cleared osteostimulative mechanism (2005) — activating genetic pathways that drive osteoblast proliferation and differentiation. The portfolio is supported by 31 FDA 510(k) clearances, 9 utility patents, ISO 13485 and MDSAP certifications, and 2+ million cumulative clinical applications with documented fusion rates above 90% in retrospective studies.

NovaBone generates revenue primarily through one-time hardware sales of its medical devices via a global exclusive distributor network (including BEGO in Europe and Summit Products Group for U.S. wound care), supplemented by private label/OEM manufacturing contracts with tier-one dental brands. The company operates a 30,000 sq ft manufacturing facility with 8,000 sq ft of ISO Class 7 clean rooms in Alachua, FL, employs 51-100 people, and maintains offices in Jacksonville, FL and a regional presence in Shenzhen, China. Recent strategic activity (2023-2025) indicates active expansion into the wound care vertical, the spine interbody fusion segment, and European dental channels through new distribution partnerships.

Name

NovaBone Products

Legal name

NovaBone Products, LLC

Website

https://novabone.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

NovaBone Products is a Florida-based biomaterials manufacturer and Halma PLC subsidiary that develops FDA-cleared synthetic bone graft substitutes and wound care devices built on its proprietary 45S5 Bioglass platform, serving dental and orthopedic surgeons across 40+ countries through distributors and private label partnerships.

Ownership category

akta.pro rank

Product category

Orthopedic & Dental Biomaterials

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Dental Equipment and Supplies Manufacturing (339114), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Dental Implants & Prosthodontic Components (Implants/Abutments/Prosthetics) (HLAHAEAE), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Periodontal Regeneration (GTR/EMD/Biologics) (HLABACAI)

Keywords

• Synthetic bone grafts
• Bioactive biomaterials
• Orthopedic surgical devices
• Dental bone regeneration
• Advanced wound care

Headquarters

HQ city

Alachua

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Synthetic Bone Graft Products: NovaBone generates revenue through the sale of its proprietary bioactive synthetic bone graft devices (NovaBone Putty, NovaBone IRM, Porous Granules) in multiple delivery formats (syringes, clamshells, cartridges). Products are sold to hospitals, surgical centers, and directly to dental and orthopedic surgeons through a global distributor network. Revenue is primarily one-time device purchase driven by surgical procedure volume.
2. Advanced Wound Care Products: Revenue from the NovaForm Wound Matrix, a collagen-based wound dressing cleared by FDA in 2023 for advanced wound care applications. Distributed through Summit Products Group in the U.S. market. Represents NovaBone's expansion into the advanced wound care market.
3. Private Label Manufacturing: NovaBone manufactures private-label wound dressings for various tier-one dental brands and other medical device companies. This OEM/OEM model provides recurring revenue from established brands seeking to leverage NovaBone's manufacturing capabilities (ISO 13485, MDSAP certified, 30,000 sq ft of manufacturing space with ISO Class 7 clean rooms).
4. International Distribution: Revenue from international markets through a network of country-specific distributors. NovaBone products are registered in 46 countries. Key markets include Europe (via BEGO partnership), Asia Pacific (China, India, Australia), Latin America, Middle East, and Africa. Each market has local distributor arrangements with product codes.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

NovaBone Products manufactures and sells proprietary synthetic bone graft substitutes and advanced wound care devices based on its 45S5 Bioglass (Calcium Sodium Phosphosilicate) technology platform. The company offers osteostimulative putties, irrigation-resistant matrices, porous granules, and collagen-based wound matrices for dental surgeons and orthopedic surgeons. NovaBone also provides OEM/private label manufacturing of wound dressings for tier-one dental brands, distributing through a global network of exclusive distributors in more than 40 countries.

Product overview

NovaBone Products is a medical device company specializing in bioactive synthetic bone graft solutions for dental and orthopedic applications. The product portfolio centers on 45S5 Bioglass-based biomaterials that harness osteostimulation properties to promote natural bone regeneration. The core offerings include NovaBone IRM (irrigation-resistant matrix) and NovaBone Putty for orthopedic applications, NovaBone Dental Putty and Porous Granules for dental procedures, and NovaForm Wound Matrix for advanced wound care. NovaBone pioneered the first FDA osteostimulative claim and offers the broadest portfolio of regenerative grafting devices with multiple delivery systems including syringes, cartridges, and clamshell formats. The company operates manufacturing facilities in Alachua, Florida with 30,000 sq ft of space including 8,000 sq ft of ISO Class 7 clean rooms, and holds 31 FDA 510(k) clearances with distribution across over 40 countries.

Differentiator

Problem solved

Functional benefit

Brands

• NovaBone IRM: Irrigation Resistance Matrix series of NovaBone grafting material designed to optimize osteogenesis with exceptional handling properties including irrigation resistance.
• NovaBone Putty
• NovaBone Dental Putty
• NovaBone Porous Granules
• NovaForm Wound Matrix

Products and services

• NovaBone Putty Synthetic bone graft substitute (putty) for orthopedic applications, ready to use out of the package, demonstrating clinical equivalence to autograft with significantly less blood loss and >90% fusion rates. Now cleared for intervertebral disc space applications alongside interbody fusion devices.
• NovaBone IRM (Irrigation Resistance Matrix) Irrigation-resistant bone grafting material for orthopedic use with exceptional handling properties, equivalence to autograft with osteogenic stimulation and angiogenic potential. Available in 2.5cc, 5cc, and 10cc volumes.
• MIS Cartridge Delivery System with Tip Minimally invasive surgery delivery system with conical tip accessory for superior precision, designed to backfill spaces as small as 3.5mm in diameter with consistent smooth putty flow. Available in 10cc and 15cc configurations.
• NovaBone Dental Putty Next-generation Calcium-Phosphosilicate bone substitute engineered for dental applications, ready to use, pre-mixed, cohesive, and moldable. Available in cartridges, syringes, and clamshell formats for periodontal/infrabony defects, ridge augmentation, extraction sites, sinus lifts, and cranio-facial augmentation.
• NovaBone Porous Granules (Dental Morsels) Next-generation synthetic bone graft with interconnected porosity (65% porosity, pore sizes up to 200 microns) for quicker bone integration and remodeling. Indicated for guided bone regeneration, ridge augmentations, and sinus elevations; resorbs over 12-18 months.
• Foot and Ankle Bioglass Syringe Delivery System NovaBone's first foot and ankle-specific 45S5 bioactive glass putty delivery system, commercially available in 2.5cc and 5cc formulations for targeted delivery in small osseous defects in foot and ankle procedures.
• NovaForm Wound Matrix FDA-cleared collagen + 45S5 bioactive glass wound care device for management of partial and full-thickness wounds including pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds. Fully resorbable, sterile, single-use, distributed in the U.S. through Summit Products Group.

Quantifiable outcome

• >90% fusion rates demonstrated in retrospective clinical studies at Sewickley Hospital (Pittsburgh, PA) and Texas Spine Care Center (San Antonio, TX)
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Summit Products GroupcoreChannel Partner/ Reseller/ Distributor · 6 May 2025NovaBone entered a long-term strategic partnership with Summit Products Group to distribute NovaForm Wound Matrix across the United States. Summit Products Group serves as a key distributor leveraging its deep distribution network and strong presence in post-acute and outpatient care settings. This partnership marks NovaBone's significant expansion into the advanced wound care market.
• BEGOcoreChannel Partner/ Reseller/ Distributor · 28 January 2025NovaBone entered a strategic distribution partnership with BEGO to bring NovaBone Dental Putty with Cartridge Dispenser to the European market. BEGO launched the product at IDS 2025 in Cologne, Germany. The partnership leverages BEGO's extensive distribution network and market leadership in European implantology to broaden NovaBone's presence in the European dental market.
• Private Label Dental PartnersminorChannel Partner/ Reseller/ Distributor · 1 January 2015Since 2015, NovaBone has been manufacturing private-label wound dressings (plugs and tapes) for various tier-one dental brands. These private label partnerships leverage NovaBone's ISO 13485 certified manufacturing capabilities and regulatory expertise to provide established brands with differentiated collagen + bioactive glass wound care products.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• botiss biomaterials: botiss biomaterials is a direct competitor in dental bone regeneration and soft tissue management, offering a portfolio of bone graft substitutes, barrier membranes, and soft tissue grafts used in implantology and periodontology. botiss competes directly with NovaBone's dental putty, granules, and collagen products in European and international markets.
• Geistlich Pharma: Geistlich Pharma is the market leader in dental bone regeneration with its Bio-Oss and Bio-Gide products. Geistlich competes directly with NovaBone's dental putty and porous granules in periodontal regeneration, sinus lifts, and implant procedures, making it the most comparable dental-focused peer.

Emerging players

• Cerapedics: Cerapedics is an emerging player in orthobiologics with its i-FACTOR peptide-enhanced bone graft used in cervical spine procedures. Cerapedics represents next-generation bone graft technology (synthetic peptide) that could compete with NovaBone's bioglass-based osteostimulation in spinal fusion indications.
• Xtant Medical: Xtant Medical is an emerging orthobiologics company offering a portfolio of bone grafts including synthetic, allograft, and demineralized bone matrix products. Xtant competes with NovaBone in spinal fusion and orthopedic bone void filling applications, particularly among cost-conscious ambulatory surgery centers.

Broad incumbents

• Medtronic: Medtronic is a broad incumbent in orthobiologics with its INFUSE Bone Graft (recombinant BMP-2) and MASTERGRAFT products used in spinal fusion and orthopedic procedures. While NovaBone competes in adjacent indications, Medtronic's bundled offerings with spinal hardware create significant indirect competitive pressure across orthopedic accounts.
• Zimmer Biomet: Zimmer Biomet is a broad orthopedic incumbent with bone graft substitute offerings used in joint reconstruction, spine, and trauma procedures. Zimmer Biomet's extensive direct sales force and hospital contracts create indirect competitive pressure on NovaBone's orthopedic product line.
• Smith & Nephew: Smith & Nephew is a broad incumbent in both advanced wound care (collagen-based skin substitutes, ALLEVYN, PICO) and orthopedics. Smith & Nephew's wound care portfolio competes with NovaBone's NovaForm Wound Matrix, while its orthopedic segment creates indirect competitive pressure in bone grafting applications.
• Baxter International: Baxter offers the Actifuse line of synthetic bone graft substitutes (silicate-substituted calcium phosphate) that compete directly with NovaBone's bioactive glass products. Baxter is a broad medtech incumbent with established orthopedic distribution channels and comparable bioactive bone graft technology.
• Integra LifeSciences: Integra LifeSciences operates in both wound care (Integra Dermal Regeneration Template) and orthopedics, making it a broad incumbent comparable to NovaBone's combined bone graft and wound matrix portfolio. Integra's regenerative tissue technologies compete in similar surgical specialties and hospital channels.
• Stryker: Stryker is a broad orthopedic incumbent offering bone graft substitutes including products inherited from the Wright Medical acquisition. Stryker competes with NovaBone in foot and ankle, trauma, and sports medicine bone grafting applications through its extensive orthopedic sales channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/novabone

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaBone Products